IBD Outcomes For Medication Therapy Management To Be Discussed at Upcoming Summit

IBD Outcomes For Medication Therapy Management To Be Discussed at Upcoming Summit
Medication Therapy Management and IBDCurant Health today announced the launch of project “A.L.I.V.E.” (Adherence and Long-term IBD Value-added Effectiveness) in partnership with the Meyerhoff Inflammatory Bowel Disease Center at the Johns Hopkins University School of Medicine. This study will allow clinicians to “implement and evaluate the effectiveness of an Inflammatory Bowel Disease (IBD) Medication Therapy Management (MTM) patient fulfillment model compared to standard care in a large university hospital setting.” The announcement was made at the Medcity ENGAGE meeting in Bethesda, Maryland, where healthcare professionals are discussing perhaps the biggest challenge in healthcare -- patient engagement. Curant Health is directly involved in addressing patient engagement, developing and implementing management protocols for chronic disease patients. IBD is a chronic condition, with the most common types being Crohn's disease (CD) and ulcerative colitis (UC). It is a disease without a cure and is associated with extremely high healthcare costs, due to its lifetime care need, reaching more than $1.8 billion dollars in total annually in the US alone. Increasingly recognized in the healthcare community is the absence of long-run reports on CD or UC. Therefore, data on Adverse Drug Events (ADE’s), hospital readmissions, and long-run adherence rates among these patients is currently very limited.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *